Eyeworld Daily News

JULY 23, 2021 | EYEWORLD DAILY NEWS | 5 FOR YOUR CATARACT SURGERY SUCCESS 1-3 SETS THE STAGE OMIDRIA FDA-APPROVED OMIDRIA: COUNT ON PERFORMANCE THAT STAYS AHEAD OF THE UNEXPECTED CME=cystoid macular edema; IFIS=intraoperative fl oppy iris syndrome; PEDs=pupil expansion devices. References: 1. OMIDRIA [package insert]. Seattle, WA: Omeros Corporation; 2017. 2. Silverstein SM, Rana VK, Stephens R, et al. Effect of phenylephrine 1.0%–ketorolac 0.3% injection on tamsulosin-associated intraoperative fl oppy-iris syndrome. OMIDRIA [package insert]. Seattle, WA: Omeros Corporation; 2017. tamsulosin-associated intraoperative fl oppy-iris syndrome. OMIDRIA [package insert]. Seattle, WA: Omeros Corporation; 2017. J Cataract Refract Surg OMIDRIA [package insert]. Seattle, WA: Omeros Corporation; 2017. J Cataract Refract Surg OMIDRIA [package insert]. Seattle, WA: Omeros Corporation; 2017. . 2018;44(9):1103-1108. 3. Visco DM, Bedi R. Effect of intracameral phenylephrine 1.0%–ketorolac Silverstein SM, Rana VK, Stephens R, et al. Effect of phenylephrine 1.0%–ketorolac 0.3% injection on Visco DM, Bedi R. Effect of intracameral phenylephrine 1.0%–ketorolac Silverstein SM, Rana VK, Stephens R, et al. Effect of phenylephrine 1.0%–ketorolac 0.3% injection on 0.3% on postoperative cystoid macular edema, iritis, pain, and photophobia after cataract surgery. tamsulosin-associated intraoperative fl oppy-iris syndrome. postoperative cystoid macular edema, iritis, pain, and photophobia after cataract surgery. tamsulosin-associated intraoperative fl oppy-iris syndrome. J Cataract Refract Surg postoperative cystoid macular edema, iritis, pain, and photophobia after cataract surgery. J Cataract Refract Surg J Cataract Refract Surg Visco DM, Bedi R. Effect of intracameral phenylephrine 1.0%–ketorolac J Cataract Refract Surg Visco DM, Bedi R. Effect of intracameral phenylephrine 1.0%–ketorolac . 2020;46(6):867-872. 4. Rosenberg ED, Nattis AS, Alevi D, et al. Visual outcomes, effi cacy, and surgical complications associated with intracameral phenylephrine 1.0%/ketorolac 0.3% administered during cataract surgery. postoperative cystoid macular edema, iritis, pain, and photophobia after cataract surgery. effi cacy, and surgical complications associated with intracameral phenylephrine 1.0%/ketorolac 0.3% administered during cataract surgery. postoperative cystoid macular edema, iritis, pain, and photophobia after cataract surgery. J Cataract Refract Surg effi cacy, and surgical complications associated with intracameral phenylephrine 1.0%/ketorolac 0.3% administered during cataract surgery. J Cataract Refract Surg Rosenberg ED, Nattis AS, Alevi D, et al. Visual outcomes, effi cacy, and surgical complications associated with intracameral phenylephrine 1.0%/ketorolac 0.3% administered during cataract surgery. Rosenberg ED, Nattis AS, Alevi D, et al. Visual outcomes, Clin Ophthalmol. 2018;12:21-28. 5. Al-Hashimi S, Donaldson K, Davidson R, et al. Medical and surgical management of the small pupil during cataract surgery. effi cacy, and surgical complications associated with intracameral phenylephrine 1.0%/ketorolac 0.3% administered during cataract surgery. Donaldson K, Davidson R, et al. Medical and surgical management of the small pupil during cataract surgery. effi cacy, and surgical complications associated with intracameral phenylephrine 1.0%/ketorolac 0.3% administered during cataract surgery. J Cataract Refract Surg. effi cacy, and surgical complications associated with intracameral phenylephrine 1.0%/ketorolac 0.3% administered during cataract surgery. J Cataract Refract Surg. effi cacy, and surgical complications associated with intracameral phenylephrine 1.0%/ketorolac 0.3% administered during cataract surgery. 2018;44(8):1032-1041. 6. Bucci FA Jr, Michalek B, Fluet AT. Comparison of the frequency of use of a pupil expansion device with and without an intracameral phenylephrine and ketorolac injection 1%/0.3% at the time of routine cataract surgery. Donaldson K, Davidson R, et al. Medical and surgical management of the small pupil during cataract surgery. AT. Comparison of the frequency of use of a pupil expansion device with and without an intracameral phenylephrine and ketorolac injection 1%/0.3% at the time of routine cataract surgery. Donaldson K, Davidson R, et al. Medical and surgical management of the small pupil during cataract surgery. J Cataract Refract Surg. AT. Comparison of the frequency of use of a pupil expansion device with and without an intracameral phenylephrine and ketorolac injection 1%/0.3% at the time of routine cataract surgery. J Cataract Refract Surg. Clin Ophthalmol. 2017;11:1039-1043. 7. Walter K, Delwadia N, Coben J. Continuous intracameral phenylephrine–ketorolac irrigation for miosis prevention in femtosecond laser–assisted cataract AT. Comparison of the frequency of use of a pupil expansion device with and without an intracameral phenylephrine and ketorolac injection 1%/0.3% at the time of routine cataract surgery. Walter K, Delwadia N, Coben J. Continuous intracameral phenylephrine–ketorolac irrigation for miosis prevention in femtosecond laser–assisted cataract AT. Comparison of the frequency of use of a pupil expansion device with and without an intracameral phenylephrine and ketorolac injection 1%/0.3% at the time of routine cataract surgery. surgery: reduction in surgical time and iris manipulation. J Cataract Refract Surg Walter K, Delwadia N, Coben J. Continuous intracameral phenylephrine–ketorolac irrigation for miosis prevention in femtosecond laser–assisted cataract J Cataract Refract Surg Walter K, Delwadia N, Coben J. Continuous intracameral phenylephrine–ketorolac irrigation for miosis prevention in femtosecond laser–assisted cataract . 2019;45(4):465-469. 8. Visco D. Effect of phenylephrine/ketorolac on iris fi xation ring use and surgical times Walter K, Delwadia N, Coben J. Continuous intracameral phenylephrine–ketorolac irrigation for miosis prevention in femtosecond laser–assisted cataract Visco D. Effect of phenylephrine/ketorolac on iris fi xation ring use and surgical times Walter K, Delwadia N, Coben J. Continuous intracameral phenylephrine–ketorolac irrigation for miosis prevention in femtosecond laser–assisted cataract in patients at risk of intraoperative miosis. surgery: reduction in surgical time and iris manipulation. in patients at risk of intraoperative miosis. surgery: reduction in surgical time and iris manipulation. Clin Ophthalmol. 2018;12:301-305. EFFECTIVELY MAINTAINS PUPIL DILATION and requires less use of PEDs 1,4-8 REDUCES COMPLICATIONS such as IFIS, CME, and breakthrough iritis 2,3 IMPROVED PATIENT EXPERIENCE with less pain, greater visual acuity, and fewer drops 1,3,4 INDICATIONS AND USAGE OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain. IMPORTANT SAFETY INFORMATION OMIDRIA must be added to irrigating solution prior to intraocular use. OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients. Systemic exposure to phenylephrine may cause elevations in blood pressure. Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-infl ammatory drugs (NSAIDs), or have a past medical history of asthma. The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacifi cation, increased intraocular pressure, and anterior chamber infl ammation. Please see the Full Prescribing Information for OMIDRIA at www.omidriahcp.com/prescribinginformation. You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. Rayner, the Rayner logo, OMIDRIA, and the OMIDRIA logo are proprietary marks of Rayner. © 2022 Rayner Surgical Inc or its affi liates, all rights reserved. EC 2022-64 04/22 US VISIT US AT BOOTH #1045

• Cover